Wysdom Radio™

Wysdom
  • 5.0 (2)
  • Medicine

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

  1. The TIPS Trade-Off: Bleeding vs. Brain

    21h ago

    The TIPS Trade-Off: Bleeding vs. Brain

    This episode tackles the "Goldilocks dilemma" of TIPS: finding the stent diameter that stops a life-threatening variceal bleed without silently destroying a patient's cognition. Metabolic Cost: A TIPS decompresses the portal system but shunts ammonia-rich blood past the liver's filter and into the brain, where it triggers the astrocyte swelling behind hepatic encephalopathy (HE).8mm vs. 10mm: The Huang meta-analysis found that 8mm stents delivered better one- and three-year survival and lower HE risk than 10mm stents, despite slightly more shunt dysfunction.6mm vs. 8mm: The Zhang RCT randomized 144 cirrhotic patients to 6mm or 8mm stents. The 6mm group had a higher 2-year rebleeding rate (35.2% vs. 24.1%) but far less overt HE (20.3% vs. 42.0%), with nearly identical survival (84.6% vs. 83.0%).Population Question: The Gong meta-analysis backs this up across mostly Asian cohorts, showing 6–7mm stents roughly halve HE risk versus 8mm without hurting survival. But the data leans on smaller Asian liver volumes and may not translate directly to Western patients.Guideline Shift: EASL now recommends small-diameter stents for patients at high risk of HE, reflecting a shift toward accepting a bit more rebleeding risk to protect the brain.Caveats: The Zhang trial was single-center and open-label, and Gong's conclusions lean on retrospective data that can't fully settle the shunt-dysfunction debate the way Huang's harder data can.Tune in to learn why the field is moving from "bigger is safer" to personalized stent sizing based on individual liver anatomy. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Zhang W, Zhang M, Xiao J, et al. Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2026;24(1):161-171. doi:10.1016/j.cgh.2025.06.023Gong J, Xia Z, Zhou Z, Chen L, Wang X, Zhou F. Effectiveness and prognosis of covered stents with different diameters in transjugular intrahepatic portosystemic shunt: a meta-analysis. Eur J Gastroenterol Hepatol. 2024;36(2):229-237. doi:10.1097/MEG.0000000000002696Huang Z, Yao Q, Zhu J, He Y, Chen Y, Wu F, Hua T. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) created using covered stents of different diameters: A systematic review and meta-analysis. Diagn Interv Imaging. 2021;102(5):279-285. doi:10.1016/j.diii.2020.11.004

    14 min
  2. New PE Guidelines: When to Intervene

    Jun 24

    New PE Guidelines: When to Intervene

    This episode breaks down the 2026 AHA/ACC/ACCP/ACPPE pulmonary embolism guidelines, highlighting the biggest changes to PE risk stratification, catheter-based interventions, and long-term follow-up. It also discusses how new randomized trials like STORM-PE and HI-PEITHO are shaping the future of interventional PE care. Biggest Change: The traditional "massive" and "submassive" PE classifications have been replaced with a new A through E risk framework, placing greater emphasis on dynamic clinical assessment and early recognition of patient deterioration.High-Risk Patient: The guidelines introduce Category D2, or normotensive shock, recognizing that patients with normal blood pressure but elevated lactate or signs of end-organ hypoperfusion may require urgent intervention.New Data Shows: Recent randomized trials demonstrated that catheter-based therapies improve right ventricular recovery and reduce clinical decompensation in intermediate-high risk PE, although long-term mortality benefits remain under investigation.Safety Pearl: The guidelines strongly caution against routine deep sedation in acute PE, noting a markedly increased risk of cardiopulmonary collapse with propofol in unstable patients.Bottom Line: These guidelines shift PE management from static risk categories to continuous reassessment and reinforce that interventional specialists should play an active role in both acute treatment and long-term follow-up.Tune in to learn how the new PE guidelines could change which patients receive intervention and when. Wysdom recommends that you check out PECompass.org.  It was founded by Dr. Mona Ranade from Stanford IR and also a co-author of this paper.  It is a great app in which you put in the clinical information about your patient and it will calculate what category your patient fits into. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.  Bulman JC, Ranade M, Sista AK, Lookstein RA, Wilkins LR. The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: Pertinent Points for the Interventional Radiologist. J Vasc Interv Radiol. Published online 2026. doi:10.1016/j.jvir.2026.108899

    22 min
  3. Embolization for Plantar Fasciitis: Technique and Early Results

    Jun 17

    Embolization for Plantar Fasciitis: Technique and Early Results

    This episode breaks down a 2026 Journal of Vascular and Interventional Radiology prospective case series evaluating transarterial embolization (TAE) as a minimally invasive treatment for chronic, refractory plantar heel pain. The study explores how targeting abnormal blood vessel growth may offer relief for patients who have exhausted traditional therapies. Clinical Problem: Nearly half of patients with plantar fasciitis remain symptomatic even after 10 years, and no single conservative treatment has consistently outperformed the others.New Approach: Rather than treating the plantar fascia itself, TAE targets the abnormal neovessels that sustain chronic inflammation and pain.Headline Result: At six months, 71% of patients responded to treatment, with major improvements in pain, quality of life, function, and a complete elimination of missed workdays among affected participants.Safety Profile: The procedure was performed as an outpatient with zero reported major adverse events and no evidence of osteonecrosis or tissue injury on follow-up MRI.Caveat: This was a small, single-center case series without a control group, so larger randomized trials are still needed to confirm how much of the benefit comes from embolization itself.Bottom Line: For patients with chronic plantar heel pain who have failed standard treatments, transarterial embolization is emerging as a promising minimally invasive option that could reshape how we approach chronic musculoskeletal pain.Tune in to learn how interventional radiology is taking on one of the most frustrating conditions in sports medicine. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.  Gill S, Hely R, Harrison B, Hely A, Landers S. Transarterial embolization to improve plantar heel pain: 6-month results from a prospective case series. J Vasc Interv Radiol. 2026;37:108688. https://doi.org/10.1016/j.jvir.2026.108688

    17 min
  4. Why PAE Made the American Urologic Association Guidelines

    Jun 10

    Why PAE Made the American Urologic Association Guidelines

    This episode breaks down a comprehensive 2024 Journal of Urology review on prostate artery embolization (PAE), exploring how it compares to transurethral resection of the prostate (TURP) and medical therapy for benign prostatic hyperplasia (BPH) and why it was added to the 2023 American Urologic Association guidelines. The episode also features expert commentary from Dr. Timothy McClure of Weill Cornell Medicine, who highlights the importance of patient selection in real-world PAE practice. Clinical Question: Can PAE relieve moderate-to-severe BPH symptoms while avoiding the bleeding, recovery time, and sexual side effects of TURP?Headline Result: Across randomized trials, PAE reduced IPSS scores by 9 to 21 points, shrank prostate volume by 20 to 30%, and outperformed both sham procedures and medical therapy in symptom relief.Safety Advantage: PAE is a same-day outpatient procedure with no postoperative catheter, near-zero transfusion risk, and strong preservation of sexual function when performed with cone beam CT guidance.Trade-Off: Symptom relief is strong, but urinary flow improvements and long-term durability remain inferior to TURP, with recurrence increasing over time.Bottom Line: For patients with larger prostates who prioritize preserving sexual function, PAE is now a guideline-supported middle ground between medication and surgery. Dr. McClure also explains why identifying the right patient is key to success.Tune in to learn which BPH patients are best suited for PAE and when surgery still makes the most sense. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Mouli S, Salem R, McClure TD. Prostate artery embolization for benign prostatic hyperplasia. J Urol. 2024;212:216-219. https://doi.org/10.1097/JU.0000000000003976

    17 min
  5. Can Thyroid Embolization Replace Surgery for Nodular Goiter?

    Jun 2

    Can Thyroid Embolization Replace Surgery for Nodular Goiter?

    This episode breaks down a JVIR retrospective study on Thyroid Artery Embolization (TAE), exploring whether embolization can serve as a non-surgical alternative for high-risk patients with massive retrosternal goiters who are poor candidates for thyroidectomy.  Clinical Problem: Many patients with large compressive goiters are too medically complex for surgery, leaving few options when airway compression and hyperthyroidism worsen symptoms. Endovascular Strategy: Using a femoral approach with selective embolization of thyroid feeders, operators intentionally leave at least one artery patent to achieve volume reduction while avoiding total gland necrosis and hypoparathyroidism. Headline Result: At six months, dominant thyroid nodule size and retrosternal extension were dramatically reduced, with most patients experiencing meaningful mechanical decompression and improved airway anatomy. Hormonal Benefit: Among patients with non-Graves hyperthyroidism, most became euthyroid after embolization, suggesting TAE may improve both compressive and endocrine symptoms. Caveat: This was a small retrospective study with mixed imaging modalities, short follow-up, and real procedural risks: including transient hyperthyroidism, hoarseness, and a reported 1.8% 30-day mortality rate. Bottom Line: For carefully selected poor surgical candidates with massive retrosternal goiters, thyroid artery embolization may offer a promising minimally invasive debulking strategy, but long-term durability still needs prospective study. Tune in to learn whether IR may soon have a larger role in managing patients traditionally sent straight to thyroid surgery. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Yilmaz S, Arıoz Habibi H, Yildiz A, Altunbas H. Thyroid embolization for nonsurgical treatment of nodular goiter: a single-center experience in 56 consecutive patients. J Vasc Interv Radiol. 2021;32:1449-1456. https://doi.org/10.1016/j.jvir.2021.06.025

    6 min
  6. Anti-platelets and venous stents: Lessons from ARIVA and C-TRACT

    May 26

    Anti-platelets and venous stents: Lessons from ARIVA and C-TRACT

    This episode breaks down the newly published ARIVA trial (Circulation), a randomized study testing whether adding aspirin to rivaroxaban after post-thrombotic iliofemoral venous stenting actually improves stent patency or simply adds bleeding risk. Clinical Question: For years, endovascular specialists have reflexively prescribed dual therapy (anticoagulation + aspirin) after venous stenting, but ARIVA asks whether aspirin is actually improving outcomes in low-flow venous systems.Result: Primary patency at six months was nearly identical, 94.8% with rivaroxaban + aspirin versus 92.4% with rivaroxaban alone, suggesting no meaningful benefit to routinely adding aspirin.Bleeding Trade-Off: While major bleeding was absent in both groups, clinically relevant non-major bleeding was more than tripled with dual therapy (8.2% vs. 2.4%), with menorrhagia emerging as a major issue in this predominantly younger female cohort.Why This Matters: When synthesized with C-TRACT, ARIVA suggests we may be overtreating venous stent patients by applying arterial antiplatelet logic to fundamentally different venous biology.Caveat: ARIVA was stopped early and excluded patients with active cancer or poor medication adherence, meaning high-risk populations still require individualized decision-making.Bottom Line: For most standard post-thrombotic iliofemoral stenting cases with good inflow and optimized IVUS-guided deployment, full-dose rivaroxaban alone may be enough without the added bleeding burden of routine aspirin.Tune in to learn whether it is finally time to stop reflexively prescribing aspirin after venous stenting. This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the articles cited below. The content was reviewed and edited by multiple healthcare professionals in the field. Barco S, Jalaie H, Sebastian T, et al. Aspirin plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis among patients with post-thrombotic syndrome: the multicenter, multinational, randomized, open-label ARIVA trial. Circulation. 2025;151:835-846. https://doi.org/10.1161/CIRCULATIONAHA.124.073050Vedantham S, Kahn SR, Marston WA, et al. Endovascular therapy for post-thrombotic syndrome — a randomized trial. N Engl J Med. 2026. https://doi.org/10.1056/NEJMoa2519001

    16 min
  7. C-TRACT Trial: Venous Stenting for Post-Thrombotic Syndrome

    May 20

    C-TRACT Trial: Venous Stenting for Post-Thrombotic Syndrome

    This episode breaks down the landmark C-TRACT trial (NEJM 2026), a phase 3 randomized study testing whether iliac vein stenting plus enhanced antithrombotic therapy actually improves outcomes in patients with moderate-to-severe post-thrombotic syndrome (PTS).  The Clinical Question: Does restoring iliac venous outflow with stenting meaningfully improve symptoms and quality of life? Result: Endovascular therapy significantly improved symptom burden, with a meaningful reduction in VCSS severity and a striking 14.5-point improvement in quality-of-life scores. Mechanical Win: Stent thrombosis was remarkably low at just 0.9%, reinforcing the importance of rigorous inflow assessment, mandatory IVUS, and aggressive stent sizing in chronic venous disease. Trade-Off: Bleeding complications were substantially higher in the intervention arm (11.6% vs. 3.6%), largely driven by prolonged dual antithrombotic therapy rather than the procedure itself. Bottom Line: For carefully selected PTS patients with good inflow and significant iliac obstruction, iliac vein stenting can deliver meaningful symptom relief, but success depends heavily on patient selection, IVUS-guided technique, and thoughtful post-op management.Tune in to learn which post-thrombotic patients actually benefit from venous stenting—and where the limits of the “open vein hypothesis” begin.

    19 min
  8. Portosystemic Shunt Embolization

    May 3

    Portosystemic Shunt Embolization

    This episode breaks down a randomized controlled trial from Hepatology exploring whether prophylactic embolization of large spontaneous portosystemic shunts (SPSS) during TIPS can prevent post-procedural hepatic encephalopathy (HE). The Core Problem: Even successful TIPS can trigger HE by shunting toxins away from the liver, especially in patients with large preexisting SPSS. The Key Strategy: Embolizing SPSS before stent deployment improves visualization and avoids catastrophic coil migration after portal decompression. A High-Impact Result: Overt HE was cut nearly in half (21% vs. 48%), with a remarkable number needed to treat (NNT) of just 4. No Increased Bleeding Risk: Closing these shunts did not increase variceal rebleeding or compromise TIPS function. The Trade-Off: The procedure adds time and briefly increases portal pressure, requiring operator confidence and careful execution. The Bottom Line: In a highly selected subset of patients, combining TIPS with SPSS embolization is a powerful, anatomy-driven approach to reduce HE risk.Tune in to learn when this added step is worth it!

    21 min
See All (38)

Ratings & Reviews

5
out of 5
2 Ratings

About

We deliver short, focused episodes on the main concepts and procedures you actually need to know. It’s the perfect clinical companion for your drive to work or your daily workout. Come learn IR on the go! Check us out at https://www.medicalwysdom.ai/

Information

  • Creator
    Wysdom
  • Years Active
    2025 - 2026
  • Episodes
    38
  • Rating
    Clean
  • Copyright
    © 2026 Wysdom
  • Show Website
    Wysdom Radio™

You Might Also Like